Biotech slump is buying opportunity

Biotechnology stocks have fallen into a bear market, leaving plenty of bargain buys on the table.

Biotechnology stocks are in a bear market. The Nasdaq Biotech index (NBI) has plunged by more than 20% since its record high in February.

In April, of the index's 121 stocks, only half a dozen or so "have managed to hold their heads above water", say Rodrigo Campos and Caroline Valetkevitch on Reuters.com. It's part of a wider trend.

"Investors are dumping what did well last year, and buying the stuff that did badly," notes the FT's James Mackintosh. Old' technology stocks, classic pharmaceuticals and emerging market shares are starting to come back into fashion in what "looks very much like a bout of profit-taking".

This does not mean biotech is doomed. The slump in stock prices actually helps the industry over the long term, says Steven Syre in The Boston Globe.

"A biotech stock collapse from even greater heights could have shut off public funding to promising new companies and for a long time limited the ability of established biotechs to grow."

The price/earnings growth (PEG) ratio suggests that biotech shares are even starting to look decent value. Generally, stocks with a PEG of below one are seen as being cheap.

More than 20 Nasdaq biotech components, including Biogen Idec (BIIB) and Gilead Sciences (GILD), now trade on PEG ratios of below one.

If you're interested in buying into the sector, The International Biotech Trust (LSE: IBT), which counts Biogen and Gilead as its top stock picks, trades on a 20% discount to its net asset value. The Biotech Growth Trust (LSE: BIOG) is on a discount of 6.7%.

Recommended

Kieran Heinemann: the history of shareholder capitalism
Investment strategy

Kieran Heinemann: the history of shareholder capitalism

Merryn talks to Kieran Heinemann, author of Playing the Market: Retail Investment and Speculation in Twentieth-Century Britain, about the history of t…
17 Sep 2021
Why it pays to face up to your investment mistakes
Investment strategy

Why it pays to face up to your investment mistakes

Buying stocks can be a complicated business. But selling stocks can be tricky, too – even if you sell for the right reasons. Max King explains how to …
17 Sep 2021
Are stockmarkets heading for a fall?
Stockmarkets

Are stockmarkets heading for a fall?

America’s S&P 500 stockmarket index has gained 30% over the past year. Valuations may be high, but that doesn't necessarily mean investors should sell…
17 Sep 2021
A nightmare 1970s scenario for investors is edging closer
Investment strategy

A nightmare 1970s scenario for investors is edging closer

Inflation need not be a worry unless it is driven by labour market shortages. Unfortunately, writes macroeconomist Philip Pilkington, that’s exactly w…
17 Sep 2021

Most Popular

The times may be changing, but don’t change how you invest
Small cap stocks

The times may be changing, but don’t change how you invest

We are living in strange times. But the basics of investing remain the same: buy fairly-priced stocks that can provide an income. And there are few be…
13 Sep 2021
Two shipping funds to buy for steady income
Investment trusts

Two shipping funds to buy for steady income

Returns from owning ships are volatile, but these two investment trusts are trying to make the sector less risky.
7 Sep 2021
Should investors be worried about stagflation?
US Economy

Should investors be worried about stagflation?

The latest US employment data has raised the ugly spectre of “stagflation” – weak growth and high inflation. John Stepek looks at what’s going on and …
6 Sep 2021